source
- Parkinson's drug pipeline diversifies as firms seek disease-modifying therapiesSeveral pharmaceutical companies are shifting away from the traditional alpha-synuclein antibody strategy and exploring alternative mechanisms to treat Parkinson's disease. AC Immune is highlighted…
- Moonwalk Biosciences raises $70M and pivots to RNAi obesity drug developmentMoonwalk Biosciences, a California biotech founded in 2024, announced a new $70 million venture funding round. The capital will support development of its first obesity drug, which uses RNA interf…